3. Discussion
breast cancer
BREAST CANCER, PROLIFERATION, LEIOMYOMA, PROLIFERATIVE, DISEASES
This is the first prospective randomized study to describe the effects on genetic expression in mammary tissue from healthy postmenopausal women during treatment with sequential MHT with either natural (EIPA Upstream Regulator Analysis (URA) and Downstream Effects Analysis (DEA) are powerful tools to assess the activity of a transcriptional regulator as well as biological functions and diseases that are downstream of genes with altered expression during treatment. The information in IPA is collected from numerous experimental systems into a continuously updated knowledge base [We found a remarkable difference between the two alternatives for sequential MHT in healthy postmenopausal women. Between-treatment FCs from Q-PCR for the 16 genes as specified in The CEE/MPA preparation conferred an augmented breast cancer risk in the WHI study. This study may contribute to some explanation for this risk, based on our results concerning breast cancer gene expression. The French E3N-cohort data indicating MHT with(EAn anti-proliferative drug in the normal breast found previously was the anti-progesterone mifepristone, where a significant down-regulation of Ki-67 protein in the breast was seen in premenopausal women treated for leiomyoma. In that study, material from an FNA biopsy was not sufficient for gene expression studies [The present gene data from the current subset of 15 + 15 patients were compared to previously reported findings on proliferation and apoptosis using the Ki-67 and Bcl-2 antibodies in the same clinical material [We also found a marked down-regulation of the proliferative prolactin gene in the EThe anti-apoptotic Bcl-2 gene was down-regulated by EThe significant positive correlation between the MKi-67 gene and Ki-67 protein expression for the total material supports the opinion that proliferative responses on both MHTs coincide with increased Ki-67 protein production and not with reduced protein degradation [